Related Experiment Videos
Mega-dose phenobarbital therapy for super-refractory status epilepticus.
Jung-Ick Byun1, Kon Chu1, Jun-Sang Sunwoo1
1Seoul National University Hospital,, Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea.
Epileptic Disorders : International Epilepsy Journal with Videotape
|November 18, 2015
Summary
Mega-dose phenobarbital (MDPB) can control super-refractory status epilepticus (SRSE) in adults when other treatments fail. While half of patients achieved seizure control, full recovery was rare, with infection and cardiorespiratory depression being key complications.
Area of Science:
- Neurology
- Critical Care Medicine
- Pharmacology
Background:
- Super-refractory status epilepticus (SRSE) presents a significant therapeutic challenge in adult patients.
- Conventional treatments often prove insufficient, necessitating exploration of alternative strategies.
Purpose of the Study:
- To evaluate the efficacy and safety of mega-dose phenobarbital (MDPB) for managing SRSE in adult patients.
- To assess outcomes and adverse events associated with MDPB treatment.
Main Methods:
- Retrospective review of 10 adult SRSE patients treated with MDPB (enteral or parenteral >10 mg/kg/day).
- Data collected included demographics, clinical features, treatment details, and SRSE outcomes.
- Outcomes were categorized to assess therapy success, failure, and adverse events.
Main Results:
- MDPB successfully controlled SRSE in 50% of patients, with a median treatment duration of 45.5 days.
- Higher serum phenobarbital levels (median 151.5 μg/ml) were achieved.
- Patients with successful MDPB therapy more often had normal brain imaging and better functional outcomes.
- Infection and cardiorespiratory depression were the most critical complications.
Conclusions:
- Mega-dose phenobarbital (MDPB) represents a viable therapeutic option for SRSE when other treatments are exhausted.
- While MDPB can control seizures, achieving full patient recovery remains challenging.
- Careful monitoring for complications like infection and cardiorespiratory depression is crucial during MDPB therapy.